Pamoat hydroxysine - Clinical pharmacology
Pamoate hydroxysine is not chemically associated with phenothiazines, reserve, meprobamate or benzodiazepines. Pamoate hydroxysine is not a cortical depressant, but its action may be related to the suppression of activity in certain key areas of the subcortical area of the central nervous system. Primary relaxation of skeletal muscles has been demonstrated experimentally. The effects of bronchodilators, as well as antihistamine and analgesic effects, have been experimentally and clinically confirmed. The antiremetic effect, both with the help of the apomorphine test and the veriloids test, has been demonstrated. Pharmacological and clinical studies show that hydroxysine in a therapeutic dose does not increase gastric secretion or acidity and in most cases has mild anti-secretory activity. Hydroxysine is rapidly absorbed from the gastrointestinal tract, and the clinical effects of Pamoate Hydroxysine are usually observed within 15-30 minutes after oral administration.
Indications and use of Pamoat hydroxysine
For symptomatic relief of anxiety and tension associated with psychoneurosis, and as an adjunct in states of organic diseases in which anxiety is manifested.
Useful in the treatment of itching due to allergic conditions such as chronic hives, atopic and contact dermatoses, as well as in histamine-mediated teeth. As a sedative when used as a premedication and after general anesthesia, hydroxysine can potentiate meridin (Demerol®) and barbiturates, so their use in preanesthetic adjuvant therapy must be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxysine is known not to interfere with the action of digitalis in any way and may be used at the same time as this drug. The effectiveness of hydroxysine as an antianxiety agent in long-term use, i.e. more than 4 months, has not been assessed by systematic clinical studies. A doctor should periodically reassess the utility of the drug for a particular patient.
Hydroxysine when administered to pregnant mice, rats and rabbits induces embryonic abnormalities in rats and mice at doses significantly exceeding the human therapeutic range. Clinical data in humans are insufficient to establish safety at early stages of pregnancy. Until such data is available, hydroxysine is contraindicated in early pregnancy.
Hydroxysine is contraindicated in patients with long QT intervals.
Pamoat hydroxysine is contraindicated in patients in whom hypersensitivity to any component of the drug has previously been detected.
is contraindicated in patients with known hypersensitivity to hydroxysine products as well as in patients with known hypersensitivity to cityrizine hydrochloride or levocetirizine hydrochloride.